Loading clinical trials...

Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Cancer | Clinical Trials | Clareo Health

UNKNOWNNA

Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Cancer

The Effect and Meaning of Designed Music Narratives on Anticipatory, Acute, and Delayed Side Effect of Chemotherapy in Children (7-12 Years) With Cancer: a Randomized Controlled Multisite Study

NCT02583139•University of Aarhus

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether a specially-designed music-narratives are effective in reducing side effects of chemotherapy in 7- to 12-year-olds with cancer.

Detailed Description

(Will be added later)

Eligibility

Age

7 - 12 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Children at the ages 7-12
•2. Four or five (dependent on their overall plan of medical treatment) consecutive courses of chemotherapy administrated at the involved child cancer units and (administered) over a period of minimum 24 hours incl. hydration with assumed moderate to severe nausea and vomiting.
•The specific type of chemotherapy may vary across the four/five consecutive courses but shall include one of the following moderate and/or highly emetogenic types of chemotherapy:
•Moderate emetogenic chemotherapy:
•* Carboplatin
•* Cyclophosphamide \<1500 mg/m2
•* Cytarabine \>1 g/m2
•* Daunorubicin
•* Doxorubicin
•* Epirubicin
+13 more criteria

Exclusion Criteria

•Previous and/or acute psychiatric diagnosis
•Cognitive and mental deficits or impaired functioning

Locations (1)

Aarhus University Hospital

Aarhus, Denmark

Key Dates

Start Date

August 1, 2014

Primary Completion Date

June 1, 2018

Completion Date

December 1, 2018

Last Updated

May 12, 2016

Enrollment

ESTIMATED participants

Conditions

CancerChemotherapy-induced Nausea and VomitingEffects of Chemotherapy

Interventions

Designed Music Narratives

BEHAVIORAL

Contacts

Ilan Sanfi, PhD

CONTACT

+4522973661 ilan@sanfi.dk

Stine C. Ærø, BA

CONTACT

+47 92498316 sero@ous-hf.no

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 12, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Cancer

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Magnetic Resonance Imaging of the Lung: Oncological Applications

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change